News|Articles|May 29, 2026

Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms

Listen

0:00 / 0:00

Key Takeaways

Surpass-Early randomized ~800 adults with ≤4-year type 2 diabetes on metformin to add tirzepatide or intensify care, predominantly with semaglutide or dulaglutide comparators.
At two years, tirzepatide yielded greater glycemic control and anthropometric benefits, with markedly higher normoglycemia rates, supporting earlier dual GIP/GLP-1 agonism when metformin response is inadequate.
Industry funding strengthens the need to contextualize effect size, but the results reinforce tirzepatide’s differentiation within incretin-based therapy on durability and magnitude of metabolic response.
Transfer experiments showed long Covid patient autoantibodies induce neurologic dysfunction in healthy mice, including with antibodies obtained two years post-infection, implicating persistent autoimmunity in a patient subset.
Commentaries emphasize strong causal evidence for autoantibody-mediated symptom generation in some long Covid cases, while cautioning against overgeneralizing to a single unifying mechanism across all phenotypes.

Research published this week highlights tirzepatide outperforming other GLP-1 therapies in early type 2 diabetes treatment while separate studies identified autoantibodies as a likely biological driver behind persistent neurological symptoms in some long Covid patients.

Two new studies shed light on distinct but significant clinical questions, one reshaping how doctors might approach early type 2 diabetes treatment, and another offering the clearest biological explanation for why some long Covid patients develop debilitating neurological symptoms.

Earlier tirzepatide use outperforms other GLP-1s in type 2 diabetes

A company-funded study found that recently diagnosed type 2 diabetes patients whose disease was not adequately controlled with metformin fared significantly better when tirzepatide was added to their regimen compared to other drugs in the GLP-1 class.¹

In the Surpass-Early trial, nearly 800 adults diagnosed with type 2 diabetes within the past four years were assigned to add either tirzepatide, sold as Mounjaro for diabetes, or other medications to their existing metformin regimen.¹ Most patients in the control group received other GLP-1 drugs including semaglutide, sold by Novo Nordisk as Ozempic and Rybelsus, or Lilly's own dulaglutide.

After two years, tirzepatide patients showed greater improvements in blood sugar control, weight, and waist circumference. Most strikingly, approximately 60% of tirzepatide patients had achieved normal blood sugar levels after two years, compared to 24% in the control group.²

The findings, published in Annals of Internal Medicine, suggest that deploying tirzepatide earlier, when standard care proves inadequate, may deliver stronger and more sustained metabolic benefits than other available approaches. The results also add to a growing body of evidence supporting tirzepatide's position as a potentially best-in-class agent in its category, though the study's industry funding warrants consideration when interpreting the magnitude of the benefit.

Autoantibodies identified as likely driver of long COVID neurological symptoms

In two other separate studies, researchers identified a potential biological mechanism behind the neurological symptoms of long Covid, finding that autoantibodies, immune system proteins that mistakenly attack the body's own tissues, may be a central cause of conditions including fatigue, pain, loss of balance, and nerve fiber damage in affected patients.³

Researchers in both studies collected autoantibodies from the blood of long Covid volunteers and infused them into healthy mice, where the mice subsequently developed neurological features closely mimicking those seen in long Covid patients.³

In one experiment, the effect was reproduced even when autoantibodies were drawn from patients two years after their initial infection, suggesting the immune dysregulation can persist long after acute illness. The studies were published in Cell Reports Medicine and Cell respectively.³

"This new awareness of the physiology of long Covid will enable us to identify a number of effective treatments for autoimmunity that could significantly improve the symptoms of millions of people with this chronic condition," said Dr. David Putrino from the Icahn School of Medicine at Mount Sinai. "Before we had no way of predicting who would benefit from therapies. Our study now shows that if you are in a subgroup of long Covid patients who have autoantibodies circulating in your body, you may be a good candidate for these drugs."

A commentary in Cell noted that the two studies provide compelling evidence that autoantibodies directly contribute to symptom generation in a subset of long Covid patients, while cautioning that neither provides definitive proof of a single central mechanism behind the condition.

Sources

Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients Reuters May 29, 2026 https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-mounjaro-tops-other-glp-1s-some-type-2-diabetes-patients-2026-05-29/
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial ACP Journals May 26, 2026 https://www.acpjournals.org/doi/10.7326/ANNALS-25-05602
A causal link between autoantibodies and neurological symptoms in long Covid Cell May 28, 2026 https://www.cell.com/cell/abstract/S0092-8674(26)00509-X

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.